171 related articles for article (PubMed ID: 37058010)
1. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Carmagnani Pestana R; Moyers JT; Roszik J; Sen S; Hong DS; Naing A; Herzog CE; Fu S; Piha-Paul SA; Rodon J; Yap TA; Karp DD; Tsimberidou AM; Pant S; Zarzour MA; Ratan R; Ravi V; Benjamin RS; Lazar AJ; Wang WL; Daw N; Gill JB; Harrison DJ; Lewis VO; Roland CL; Patel SR; Livingston JA; Somaiah N; Ludwig JA; Conley AP; Hamerschlak N; Gorlick R; Meric-Bernstam F; Subbiah V
Clin Cancer Res; 2023 May; 29(9):1708-1718. PubMed ID: 37058010
[TBL] [Abstract][Full Text] [Related]
2. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
[TBL] [Abstract][Full Text] [Related]
3. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
5. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
7. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).
Moyers JT; Pestana RC; Roszik J; Hong DS; Naing A; Fu S; Piha-Paul S; Yap TA; Karp D; Rodon J; Livingston A; Zarzour MA; Ravi V; Patel S; Benjamin RS; Ludwig J; Herzog C; Ratan R; Somaiah N; Conley A; Gorlick R; Meric-Bernstam F; Subbiah V
Clin Cancer Res; 2023 Jan; 29(2):401-409. PubMed ID: 36288393
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
[TBL] [Abstract][Full Text] [Related]
9. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
10. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
11. Relevant Trials Update in Sarcomas and Gastrointestinal Stromal Tumors: What Surgeons Should Know.
Callegaro D; Roland CL; Raut CP
Surg Oncol Clin N Am; 2022 Jul; 31(3):341-360. PubMed ID: 35715138
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.
Nagatani Y; Shitara K; Bando H; Kuboki Y; Okamoto W; Kojima T; Yoshino T; Nishida T; Ohtsu A; Doi T
BMC Cancer; 2016 Nov; 16(1):889. PubMed ID: 27842521
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.
Boilève A; Dufresne A; Chamseddine A; Nassif E; Dumont S; Brahmi M; Adam J; Rouleau E; Karanian M; Haddad V; Faron M; Honoré C; Meeus P; Le Cesne A; Blay JY; Mir O
ESMO Open; 2020 Nov; 5(6):e001082. PubMed ID: 33246932
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Garcia del Muro X; Lopez-Pousa A; Martin J; Buesa JM; Martinez-Trufero J; Casado A; Poveda A; Cruz J; Bover I; Maurel J;
Cancer; 2005 Oct; 104(8):1706-12. PubMed ID: 16134177
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
[TBL] [Abstract][Full Text] [Related]
19. Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials.
Comandone A; Petrelli F; Boglione A; Barni S
Oncologist; 2017 Dec; 22(12):1518-1527. PubMed ID: 28835514
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
